Clinical trial teams now face a harder choice when they buy new technology. Speed still matters, but it can't be the only test. ICH E6(R3), adopted in January 2025, puts more focus on quality by design, risk-based oversight, fit-for-purpose systems, and clear control of trial processes. A tool may save time and still be a poor fit if teams can't explain its output, check its limits, or link it to a clear trial decision. The ICH E6(R3) Good Clinical Practice guideline supports this approach.
Trial scale adds another layer. ClinicalTrials.gov listed 596,902 studies on August 3, 2026, including 64,697 recruiting studies. It also reported that 66% of recruiting studies were outside the United States. Sponsors often work across many countries, site models, study types, and data flows. The ClinicalTrials.gov study trends show why one technology path won't suit every trial.
What decision do you need the system to improve?
Start with the decision that needs better evidence. A protocol team may want to spot avoidable complexity before a study starts. An operations team may need earlier signs that enrollment is moving off plan. A quality team may need help finding gaps between SOPs and current rules.
These are separate problems. Each one uses different data and carries a different risk if the output is wrong. That is why AI-Powered Clinical Trial Solutions should be judged by the exact decision they support. Calance presents separate uses for protocol complexity review, enrollment forecasting, and regulatory or SOP gap checks. This helps teams compare the tool with the task instead of treating one system as the answer to every trial problem.
Which trial variables should guide the choice?
Protocol complexity is one key variable. A 2025 peer-reviewed study created a protocol complexity tool with 26 questions across 5 areas. Researchers tested it on difficult phase II to IV trials. Complexity scores fell in 12 of 16 trials after review. The study also found that higher complexity scores were linked with slower site activation and recruitment. The protocol complexity study supports the value of early review.
That finding points to a clear path. If protocol burden can delay site start-up or recruitment, teams may gain more by finding the burden before launch. Clinical Trials Solutions used for this job should show what creates the score and which parts of the protocol drive it. Teams also need a clear review step before they act on the result.
Enrollment risk needs a different path. A forecast needs current site data, a clear enrollment target, a useful time window, and rules for action when recruitment falls away from plan. A forecast has little value if no one knows what to do when the result changes.
When does AI fit the trial process?
AI fits best when the task has repeatable data, a clear use case, and people who can review the output. In January 2026, FDA and EMA published 10 principles for good AI practice in drug development. The principles cover context of use, records, human oversight, model checks, and life-cycle management. The FDA principles for good AI practice give teams a useful basis for review.
These points matter because risk changes from task to task. A low-risk document sort may allow more automation. A model that affects participant monitoring, eligibility review, or a regulatory decision needs much stronger control. Solutions For Clinical Trials should therefore be judged by the risk of the decision, the chance of error, and the way people can detect or correct that error.
Buyers should ask for proof that matches the planned use. A broad accuracy claim isn't enough. Teams need to know what data were used and what the model was built to do. They also need to know what limits were found and what happens when the model is unsure.
What tradeoffs should buyers accept?
One tradeoff is speed versus review effort. A system may scan a large file set quickly, but that gain can disappear if reviewers can't trace why a record was flagged. Another tradeoff is model strength versus day-to-day fit. A strong model may still fail in practice if it needs data the team doesn't have or if staff must change too much of their work.
Calance has published a clinical trial complexity scoring case study about a document-processing system that scores patient, site, and study complexity. The case also describes a review step where subject-matter experts can adjust selected measures. This type of review loop is worth testing during selection. Vendor case results should still be checked against the buyer's own protocol mix, data quality, and acceptance rules.
Which warning signs should stop the selection process?
A clear warning sign is choosing a product category before defining the problem. Another is a model that gives a score or forecast without showing the data period, assumptions, or review path behind it. Buyers should also be careful when a vendor talks about platform-level validation while the planned use depends on a different therapy area, document type, patient group, or work process.
Regulatory fit needs the same level of care. ICH E6(R3) says trial systems should be fit for purpose. It also says quality management should focus on factors that may affect participant safety and trial reliability. Teams should know who reviews exceptions and who can override an output. They should also know how model or data changes are recorded.
A system should have clear limits. If a team can't tell when the model may fail, it is hard to set safe use rules. This matters most when the output can change a high-impact trial decision.
What should the final selection framework confirm?
Choose the path that improves one named decision and can be controlled in the trial setting where it will be used. Before approval, confirm that the input data fit the intended use. The output should have an owner and a clear action. Validation should also cover the risk created by that use.
The last review should separate proof from possibility. Ask what has been tested on data like yours. Check what failure modes were found and what happens when the system is unsure. For protocol review, find out if the method spots burden early enough to change the design. For enrollment forecasting or compliance review, check how often the model is updated and how teams respond to exceptions.
Frequently asked questions
How should sponsors compare clinical trial technology options?
Sponsors should start with one clear decision. They should then check the data needed and the risk of a wrong output. The human review process also needs to match the planned use. This keeps the choice tied to trial needs instead of product claims.
Is AI right for every clinical trial process?
No. AI works better when the task has repeatable inputs and an output that people can check. High-impact uses need stronger review because an error may affect participant safety or trial reliability. Teams should set controls based on the risk of the task.
What should teams check before using AI for protocol review?
Teams should check protocol formats, source quality, scoring rules, and the review process for flagged items. They should also test whether the output appears early enough to support a design change. Validation should use protocols that are close to the studies the system will review. This gives a better view of real use.
What makes enrollment forecasting useful?
A forecast is useful when it leads to a clear action. Teams need a target enrollment curve and current site data. They also need a rule for when to step in and who owns the response. Without those steps, the forecast may describe a problem without helping the team fix it.
What should buyers monitor next?
Buyers should watch how regulators apply current AI guidance in real review and inspection work. They should also track how ICH E6(R3) changes sponsor quality systems and technology controls. Those signals will show which checks are becoming normal for AI used in regulated trial work. They can also help buyers update their own review standards.
For more details, Click Here
Get In Touch
Mail Id: [email protected]
Comments
Log in or sign up to join the conversation.